Sie suchten nach: maropitant (Maltesisch - Englisch)

maropitant
maropitant

cerenia 16 mg maropitant
cerenia 16 mg maropitant

maropitant huwa effettiv kontra remettar.
maropitant is effective against vomiting.

cerenia 160 mg pilloli għal klieb maropitant
cerenia 160 mg tablets for dogs maropitant

cerenia 10 mg/ml injezzjoni għal klieb u qtates maropitant
cerenia 10 mg/ml injection for dogs and cats maropitant

maropitant (bħala ċitrat ta’ maropitant monoidrat) 10 mg.
maropitant (as maropitant citrate monohydrate) 10 mg .

kull pillola fiha 16 mg maropitant bħala ċitrat monoidrat ta ’ maropitant.
each tablet contains 16 mg maropitant as maropitant citrate monohydrate.

cerenia 10 mg/ml soluzzjoni għall-injezzjoni għal klieb u qtates maropitant
cerenia 10 mg/ml solution for injection for dogs and cats maropitant

10 mg maropitant għal kull ml bħala ċitrat monoidrat ta ’ maropitant metacresol bħala preservattiv.
metacresol as preservative.

studji f’laboratorju wrew li maropitant jista’ jkun irritanti għall-għajnejn.
in laboratory studies, maropitant has been shown to be a potential eye irritant.

1 ml ta’ soluzzjoni fiha 10 mg maropitant (bħala ċitrat ta’ maropitant monoidrat)
1 ml of solution contains 10 mg maropitant (as maropitant citrate monohydrate).

kull pillola fiha 16 mg, 24 mg, 60 mg jew 160 mg maropitant bħala ċitrat monoidrat ta’ maropitant.
each tablet contains 16 mg, 24 mg, 60 mg or 160 mg maropitant as maropitant citrate monohydrate.

waqt studji kliniċi il-livelli ta’ maropitant fil-plażma bdew jgħatu effett siegħa wara l- amministrazzjoni.
during clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration.

cerenia m’għandhiex tintuża flimkien ma’ ca-channel antagonists billi maropitant għandu affinità għal ca-channels.
cerenia should not be used concomitantly with ca-channel antagonists as maropitant has affinity to ca-channels.

maropitant jiġi mmetabolizzat fil-fwied u għalhekk għandu jintuża b’kawtela fi klieb u qtates b’mard fil- fwied.
maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease.

maropitant jiġi mmetabolizzat fil-fwied u għalhekk għandu jintuża bil-għaqal f’pazjenti b’mard fil-fwied.
maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease.

cyp2d15 u cyp3a12 kienu identifikati bħala l- forom fil - klieb involuti fil- biotrasformazzjoni ta ’ maropitant fil- fwied.
cyp2d15 and cyp3a12 were identified as the canine isoforms involved in the hepatic biotransformation of maropitant.

mill-forma maġġuri ta’ maropitant, 10.4% ġie irkuprat fl-urina u 9.3% fl-ippurgar.
for the major metabolite 10.4% of the maropitant dose was recovered in urine and 9.3% in faeces.

fuq in- naħa ta ’ quddiem, kull nofs hu immarkat bl- ittri “ mpt ” u numri li juru il kwantità ta ’ maropitant.
on the obverse side, each half is marked with the letters “ mpt” and figures denoting the quantity of maropitant.